CELLIVITY / ADULT ACCESS
Are you 18 or older?
CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
CELLIVITYLevel E marks a central question without dependable direct human evidence; read the outcome conclusion rather than treating the letter as a direction of effect.
This E grade answers the central longevity question only. Other outcomes are graded separately below.A broccoli-derived compound studied in cellular-defence signalling. Formulation and conversion strongly affect measured exposure, but exposure is not efficacy and no human trial shows longer lifespan or validated healthspan.
Outcome map
Evidence can be stronger for a specific marker or population and weaker for a broader promise. Each row answers a separate question.
No completed human intervention reviewed tested and demonstrated longer lifespan or an improvement in validated healthspan.
One direct crossover showed greater urinary metabolite recovery with verified active myrosinase under exact single-dose conditions; this is exposure, not efficacy.
A higher urinary exposure proxy cannot establish a health benefit, validate another formulation or prove finished-product equivalence.
One modest surrogate result exists, but protocol and analysis changes, attrition, a null HbA1c result and no clinical endpoint limit generalization.
The reviewed evidence does not establish prevention or treatment of diabetes, cancer, infection, autism, schizophrenia or other disease.
Recurrent gastrointestinal effects and heterogeneous short studies do not establish universal, long-term or interaction-free safety.
A broccoli-derived isothiocyanate studied in cellular defence signalling. Glucoraphanin precursor, active myrosinase, preformed sulforaphane and direct stabilized formulations are not interchangeable, and urinary recovery is an exposure proxy rather than a clinical benefit.
Formulation-specific crossover studies show that verified active myrosinase and preformed sulforaphane can increase urinary metabolite recovery relative to glucoraphanin alone. Clinical evidence remains outcome-specific and largely limited to modest surrogates, exploratory or mixed rating-scale findings and informative null trials. No completed human intervention demonstrates longer lifespan or validated healthspan.
Concentrated formulations can cause gastrointestinal effects, and exact source, conversion, stability and dose matter. Small, selected and heterogeneous trials do not establish universal, long-term or interaction-free safety.
This science review does not establish a Thailand market route. Ingredient source, formulation and finished-product status require separate official confirmation.
Sources + indexes
Open the linked research and official records behind this guide. Early topics may begin with a research index while stronger sources are added.